Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.

Ha, Huan T; Griffith, Kent A; Zalupski, Mark M; Schuetze, Scott M; Thomas, Dafydd G; Lucas, David R; Baker, Laurence H; Chugh, Rashmi

Ha, Huan T; Griffith, Kent A; Zalupski, Mark M; Schuetze, Scott M; Thomas, Dafydd G; Lucas, David R; Baker, Laurence H; Chugh, Rashmi.

Affiliation

Ha HT; Moses Cone Reg Cancer Ctr., Greensboro, NC, USA.

Am J Clin Oncol ; 36(1): 77-82, 2013 Feb.

Article in En | MEDLINE | ID: mdl-22237145

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Bone Neoplasms/drug therapy; Sarcoma/drug therapy; Soft Tissue Neoplasms/drug therapy; Adult; Aged; Antibodies, Monoclonal, Humanized; Bone Neoplasms/genetics; Bone Neoplasms/mortality; Cetuximab; Disease-Free Survival; ErbB Receptors/biosynthesis; ErbB Receptors/genetics; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Sarcoma/genetics; Sarcoma/mortality; Soft Tissue Neoplasms/genetics; Soft Tissue Neoplasms/mortality; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Soft Tissue Neoplasms / Bone Neoplasms / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Clin Oncol Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google